

*Supplemental Materials for*

**Decline of SARS-CoV-2 specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days  
after hospital discharge**

**Supplemental Table 1**

**Supplemental Table 2**

**Supplemental Figure 1**

**Materials and Methods**

**Supplemental Table 1.** Information of the 27 convalescent COVID-19 patients

<b>Patients No.</b>	<b>Disease severity</b>	<b>Underlying illness</b>	<b>Days between revisit and discharge</b>
1	Critically ill	1, 2, 3, 4	38
2	Severe	None	85
3	Severe	2	95
4	Severe	5	94
5	Severe	None	94
6	Moderate	6	29
7	Moderate	None	29
8	Moderate	7	31
9	Moderate	None	87
10	Moderate	None	28
11	Moderate	None	91
12	Moderate	None	85
13	Moderate	None	87
14	Moderate	None	91
15	Moderate	2, 6, 8	92
16	Moderate	None	92
17	Moderate	None	94
18	Moderate	2, 9	93
19	Moderate	None	95
20	Moderate	None	94
21	Moderate	None	93
22	Moderate	None	92
23	Moderate	None	91
24	Moderate	None	99
25	Moderate	2, 6, 10	89
26	Mild	None	91
27	Mild	None	92


Underlying illness: 1. Coronary heart disease; 2. Hypertension; 3. Cholecystectomy; 4. Benign prostatic hyperplasia; 5. Car accident caused multiple soft tissue injuries and intracranial hemorrhage (improved after conservative treatment); 6. Diabetes; 7. Nasal drip syndrome; 8. Breast cancer surgery; 9. Parkinson; 10. Hyperlipidemia.

**Supplemental Table 2. RLU reading of 40x-diluted serum samples**

Patient No.	IgG		IgM		IgA	
	Serum <sup>1*</sup>	Serum <sup>2#</sup>	Serum <sup>1*</sup>	Serum <sup>2#</sup>	Serum <sup>1*</sup>	Serum <sup>2#</sup>
1	192570	225755	121525	171927	4181528	119664
2	787917	481707	462080	228989	755996	117120
3	373114	115530	269442	169600	2550186	103186
4	1016734	409123	349147	21924	6287723	581507
5	1088180	527618	192798	23016	370290	58370
6	1103871	430981	1044559	95108	420981	56523
7	37331	46142	326007	101621	592952	142368
8	615685	176486	97887	71463	325506	13308
9	81647	21084	44220	27264	362556	14062
10	320733	610774	1016124	11761	676145	977108
11	231340	94211	103723	27103	615535	167301
12	211033	35451	96228	143261	493764	33588
13	663868	213473	399370	44164	658249	59461
14	494716	247401	1037860	1626895	1599866	85258
15	463784	104331	153542	16551	558550	201944
16	804726	84526	447887	107921	538584	36069
17	491644	172531	615959	43681	145772	12737
18	967907	257183	125124	16284	792559	149856
19	705879	75144	195375	30612	1445568	61494
20	838185	86520	79849	11591	245369	39687
21	13450	90284	40425	245028	131176	45502
22	848789	133443	592558	106593	1082316	49915
23	76594	92837	1480652	337414	314868	395386
24	692402	50411	625029	100381	271754	20564
25	1553163	238563	337777	23549	1629610	39348
26	79832	16624	91794	69160	84097	7962
27	23189	22292	8815	2648	34894	14215

\*The serum samples collected at discharge.

# The serum samples collected at revisit.



**Supplemental Figure 1.** Changes of SARS-CoV-2 RBD-specific serum IgG, IgM and IgA levels in one convalescent patients (patient No. 11) at revisit 45 and 91 days after discharge.

## Materials and Methods

Thirty COVID-19 convalescent patients discharged from the Affiliated Hospital of USTC and three patients discharged from the First Affiliated Hospital of Anhui Medical University agreed to participate a longitudinal study of measuring the levels of IgG, IgM and IgA in their blood. Their venous blood samples were collected during a revisit at clinic, serum samples were collected by centrifugation. All serum samples were diluted 40-times with dilution buffer and then measured using the SARS-CoV-2 specific IgG, IgM and IgA kits (Ma H et al., 2020) and a fully automatic chemical luminescent immunoanalyzer, Kaiser 1000 (Kangrun Biotech, Guangzhou, China). The detected chemiluminescent signal over background signal was shown as relative light units (RLU). Cut-Off Index (COI) is the ratio of RLU Signal / Cut-Off value, and used in Figure 1 plotting and the following calculation. The Cut-off value of serum IgG, IgM and IgA kit was 9971, 17358 and 32189, respectively, determined previously (Ma H et al., 2020).

COI variables between group of discharge and revisit were compared, based on a paired t-test using PRISM version 6.0. The p values for the difference between discharge and revisit are < 0.0001, 0.0023 and 0.0020 for IgG, IgM and IgA, respectively. A p value less than 0.05 is judged statistically significant.

We also attempted to estimate decline rates of virus-specific antibodies using a previously established exponential decay model of antibody decline kinetics after infection (Teunis et al., 2016). In this model, the SARS-CoV-2 specific antibody concentration follows an exponential decay along with time, after it reached a peak at recovery (shortly before or at discharge when we did first measure). The model can be formulated as

$$y_k(t) = y_{0,k} \exp(-\tau_k t), \quad k = 1, 2, 3 \text{ for } IgG, IgM \text{ and } IgA$$

Where  $y_k(t)$  is SARS-CoV-2 specific antibody concentration measured at date at revisit,  $y_{0,k}$  is the antibody concentration measured at discharge.  $t$  is a number of days between the discharge and revisit (days after discharge).  $\tau_k$  is the decay rate of virus-specific antibody, which is different for each type of antibody and needs to be determined from the data of this group of 27 patients. For presenting the data shown in Figure 1 D-F and calculating  $\tau_k$  (for IgG, IgM and IgA respectively), we re-write the mathematical formula as

$$\ln [y_k(t) / y_{0,k}] = -\tau_k t$$

Where  $y_k(t) / y_{0,k}$  = ratios of COI (or RLU) of Ig levels at revisit (day  $t$ ) versus at discharge (Day 0).

For IgG, the estimated decay rate  $\tau_k$  is 0.015 with p-value 3.7e-9. The predicted days when patients' SARS-CoV-2 specific IgG decline to the background level (COI = 1.0) are 273 days (mean), ranging from 134 to 304 days (95% confidence interval).

For IgM, the estimated decay rate  $\tau_k$  is 0.019 with p-value 9.9e-7. The predicted days when patients' IgM declines to the background level are 150 days (mean), ranging from 50-213 days (95% confidence interval).

For IgA, the estimated decay rate  $\tau_k$  is 0.026 with p-value 2.36e-10. The predicted days when patients' IgA declines to the background level are 108 days (mean), ranging from 40-181 days (95% confidence interval).